RegulatoryCompany release

Taysha completes TSHA-102 PPQ campaign and reports no severe treatment-related SAEs in 33 patients

Taysha Gene Therapies, Inc. · Thu 12 Nov 2026

The Rett syndrome gene therapy developer says validation batches met specifications, with an FDA CMC meeting due this quarter and BLA-pathway feedback expected in the first half of 2027.

Taysha Gene Therapies reported third-quarter results on 12 November 2026 and said it has finished the process performance qualification (PPQ) manufacturing campaign for TSHA-102, its AAV-based gene therapy for Rett syndrome. The campaign is intended to support a future biologics licence application (BLA).

According to the company, the PPQ batches met their predefined specifications and the comparability criteria. The summary provided does not give batch numbers, scale or the specific comparability parameters assessed.

On safety, Taysha said no severe treatment-related serious adverse events and no dose-limiting toxicities had been observed among 33 treated patients as of the November 2026 data cutoff.

The company expects to hold a Type B CMC meeting with the US Food and Drug Administration in the fourth quarter of 2026, with the agency's feedback anticipated in the first quarter of 2027. Six-month interim data from the pivotal study, along with FDA feedback on the BLA pathway, are expected in the first half of 2027.

For context, a Type B meeting is a formal FDA meeting that lets sponsors seek agency input at key development milestones, including on chemistry, manufacturing and controls.

What it means for your team

  • Completion of PPQ and the comparability results are central to the CMC package for a gene therapy BLA; the planned Type B meeting will test how FDA views that data.
  • Quality teams should watch the Q1 2027 FDA feedback for any expectations on comparability, specifications or process validation for AAV products.
  • The safety statement covers 33 patients to a November 2026 cutoff and is a company report; formal data and pivotal interim results are not due until the first half of 2027.
  • Market-access and regulatory planners can treat 1H 2027 as the key window for clarity on the BLA pathway for TSHA-102.

Company's press release: Taysha Gene Therapies, Inc. ↗

Article written by VigiEye from the official source (Taysha Gene Therapies, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Regulatory All →